Aquestive Therapeutics (AQST)
Aquestive Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
28.7M
Short interest
settlement 2026-09-30
13.1
Days to cover
+1.3 days vs prior
65.6%
Short share of volume
2026-10-23
2,179
Fails to deliver
settlement 2026-09-25
Wed 4 Nov
Next earnings
estimated date
-$379K
Insider flow, 90 days
0 buys, 4 sells
As of 2026-10-23.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in AQST is 28,748,212 shares, up 3,269,430 shares over the last month. Over the last 48 readings it ranged from 8,411,354 shares (15 August 2025) to 28,748,212 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 2.2M shares a day that is 13.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/aqst" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 28,748,212 | +5.8% | 2,201,111 | 13.06 |
| 2026-09-15 | 27,161,738 | +6.6% | 2,299,068 | 11.81 |
| 2026-08-31 | 25,478,782 | +21.6% | 3,562,981 | 7.15 |
| 2026-08-14 | 20,951,747 | +16.1% | 4,038,195 | 5.19 |
| 2026-07-31 | 18,048,004 | +8.2% | 2,024,303 | 8.92 |
| 2026-07-15 | 16,674,440 | +4.2% | 1,529,976 | 10.90 |
| 2026-06-30 | 15,996,883 | +8.1% | 3,032,294 | 5.28 |
| 2026-06-15 | 14,797,738 | -2.9% | 1,550,105 | 9.55 |
| 2026-05-29 | 15,239,186 | +1.4% | 1,414,928 | 10.77 |
| 2026-05-15 | 15,033,627 | -3.0% | 2,023,805 | 7.43 |
| 2026-04-30 | 15,497,249 | -0.1% | 1,228,894 | 12.61 |
| 2026-04-15 | 15,520,449 | -11.6% | 991,020 | 15.66 |
| 2026-03-31 | 17,555,797 | -0.7% | 1,739,317 | 10.09 |
| 2026-03-13 | 17,684,928 | -11.4% | 2,410,492 | 7.34 |
| 2026-02-27 | 19,954,296 | -0.4% | 1,972,294 | 10.12 |
| 2026-02-13 | 20,036,340 | -1.7% | 8,842,120 | 2.27 |
| 2026-01-30 | 20,386,052 | +0.4% | 3,997,304 | 5.10 |
| 2026-01-15 | 20,296,603 | -15.9% | 8,996,718 | 2.26 |
| 2025-12-31 | 24,139,081 | +10.1% | 2,332,018 | 10.35 |
| 2025-12-15 | 21,919,352 | +10.6% | 2,180,401 | 10.05 |
| 2025-11-28 | 19,825,552 | +3.3% | 2,757,613 | 7.19 |
| 2025-11-14 | 19,196,523 | +30.2% | 3,261,143 | 5.89 |
| 2025-10-31 | 14,739,130 | +20.3% | 2,717,822 | 5.42 |
| 2025-10-15 | 12,252,965 | +5.8% | 3,225,551 | 3.80 |
| 2025-09-30 | 11,580,083 | +30.4% | 4,804,090 | 2.41 |
| 2025-09-15 | 8,880,063 | -4.3% | 3,364,972 | 2.64 |
| 2025-08-29 | 9,274,353 | +10.3% | 1,428,924 | 6.49 |
| 2025-08-15 | 8,411,354 | -10.9% | 1,451,410 | 5.80 |
| 2025-07-31 | 9,442,487 | -5.7% | 1,079,132 | 8.75 |
| 2025-07-15 | 10,009,133 | -10.5% | 1,159,487 | 8.63 |
| 2025-06-30 | 11,181,713 | -6.8% | 1,533,379 | 7.29 |
| 2025-06-13 | 12,003,700 | +7.8% | 1,809,121 | 6.64 |
| 2025-05-30 | 11,138,891 | +13.2% | 1,280,001 | 8.70 |
| 2025-05-15 | 9,840,455 | +4.6% | 2,089,368 | 4.71 |
| 2025-04-30 | 9,407,433 | -4.7% | 985,694 | 9.54 |
| 2025-04-15 | 9,870,823 | -1.5% | 1,397,874 | 7.06 |
| 2025-03-31 | 10,021,362 | -2.0% | 1,345,638 | 7.45 |
| 2025-03-14 | 10,228,131 | +2.5% | 1,348,501 | 7.58 |
| 2025-02-28 | 9,978,681 | +0.0% | 1,654,796 | 6.03 |
| 2025-02-14 | 9,977,136 | -10.0% | 2,655,726 | 3.76 |
| 2025-01-31 | 11,086,624 | -6.0% | 1,177,340 | 9.42 |
| 2025-01-15 | 11,788,486 | +12.4% | 1,745,887 | 6.75 |
| 2024-12-31 | 10,483,849 | +8.6% | 1,500,236 | 6.99 |
| 2024-12-13 | 9,653,937 | -4.9% | 1,696,232 | 5.69 |
| 2024-11-29 | 10,150,852 | +1.9% | 1,255,654 | 8.08 |
| 2024-11-15 | 9,965,234 | -1.8% | 1,873,758 | 5.32 |
| 2024-10-31 | 10,143,690 | -6.0% | 1,390,945 | 7.29 |
| 2024-10-15 | 10,790,957 | -2.5% | 983,521 | 10.97 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 23 October 2026, the short share of AQST volume is 65.6%, up 7.3 points over the last five sessions. Over the last 30 readings it ranged from 26.3% (25 September 2026) to 73.7% (19 October 2026). The latest reading is 17.7 points above the 30-session average of 47.9%, on 981K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-23 | 643K | 981K | 65.6% | 288 |
| 2026-10-22 | 295K | 560K | 52.7% | 0 |
| 2026-10-21 | 371K | 762K | 48.7% | 0 |
| 2026-10-20 | 449K | 1.1M | 40.6% | 480 |
| 2026-10-19 | 1.2M | 1.6M | 73.7% | 1,124 |
| 2026-10-16 | 1.5M | 2.6M | 58.3% | 138,933 |
| 2026-10-15 | 1.4M | 2.7M | 53.0% | 71,264 |
| 2026-10-14 | 376K | 721K | 52.1% | 14 |
| 2026-10-13 | 199K | 571K | 34.9% | 1,100 |
| 2026-10-12 | 129K | 408K | 31.7% | 0 |
| 2026-10-09 | 301K | 657K | 45.8% | 36 |
| 2026-10-08 | 256K | 697K | 36.7% | 2,944 |
| 2026-10-07 | 232K | 684K | 33.9% | 0 |
| 2026-10-06 | 287K | 568K | 50.5% | 0 |
| 2026-10-05 | 210K | 471K | 44.5% | 20 |
| 2026-10-02 | 532K | 1.1M | 46.5% | 0 |
| 2026-10-01 | 467K | 1.1M | 44.0% | 100 |
| 2026-09-30 | 367K | 861K | 42.6% | 0 |
| 2026-09-29 | 394K | 902K | 43.7% | 231 |
| 2026-09-28 | 204K | 591K | 34.4% | 10 |
| 2026-09-25 | 230K | 873K | 26.3% | 10,575 |
| 2026-09-24 | 752K | 1.5M | 48.7% | 1,194 |
| 2026-09-23 | 564K | 1.0M | 55.4% | 210 |
| 2026-09-22 | 468K | 850K | 55.1% | 1,451 |
| 2026-09-21 | 501K | 922K | 54.4% | 5,200 |
| 2026-09-18 | 444K | 914K | 48.6% | 320 |
| 2026-09-17 | 621K | 1.1M | 54.3% | 2,884 |
| 2026-09-16 | 328K | 593K | 55.3% | 0 |
| 2026-09-15 | 328K | 558K | 58.8% | 0 |
| 2026-09-14 | 521K | 1.1M | 46.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 25 September 2026, the fails-to-deliver balance in AQST is 2,179 shares, up 2,176 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (23 September 2026) to 670,550 shares (18 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-25 | 2,179 | $4.82 | $11K |
| 2026-09-23 | 3 | $4.95 | $15 |
| 2026-09-17 | 5,775 | $4.82 | $28K |
| 2026-09-14 | 11,667 | $4.78 | $56K |
| 2026-09-11 | 187 | $4.99 | $933 |
| 2026-09-04 | 30,415 | $5.35 | $163K |
| 2026-09-03 | 26,784 | $5.38 | $144K |
| 2026-09-02 | 1,374 | $5.24 | $7K |
| 2026-08-27 | 244 | $5.39 | $1K |
| 2026-08-18 | 670,550 | $4.29 | $2.9M |
| 2026-08-17 | 528,217 | $4.25 | $2.2M |
| 2026-08-14 | 17,206 | $4.25 | $73K |
| 2026-08-11 | 100,006 | $4.29 | $429K |
| 2026-08-06 | 184,766 | $3.76 | $695K |
| 2026-08-05 | 35 | $3.74 | $131 |
| 2026-08-03 | 7,019 | $3.70 | $26K |
| 2026-07-28 | 35,018 | $3.73 | $131K |
| 2026-07-22 | 3,118 | $4.04 | $13K |
| 2026-07-20 | 3,400 | $4.12 | $14K |
| 2026-07-16 | 44,737 | $3.95 | $177K |
| 2026-07-15 | 44,704 | $4.04 | $181K |
| 2026-07-02 | 1,165 | $4.24 | $5K |
| 2026-06-30 | 7,164 | $4.16 | $30K |
| 2026-06-29 | 997 | $4.39 | $4K |
| 2026-06-24 | 27,015 | $5.03 | $136K |
| 2026-06-23 | 2,438 | $4.72 | $12K |
| 2026-06-22 | 3,472 | $4.71 | $16K |
| 2026-06-18 | 704 | $4.43 | $3K |
| 2026-06-16 | 567 | $4.22 | $2K |
| 2026-06-15 | 55 | $4.17 | $229 |
Insider trades
SEC Form 4, newest first. JSONInsiders at AQST reported 4 open-market sells worth $379K in the last 90 days and no open-market buys. Latest filing: Cochran John (Director) on 2026-10-21.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-21 | Cochran John | Director | Other transaction | 62K | $0.00 | $0 | 162K |
| 2026-10-15 | Barber Daniel | President and CEO | Sell | 25K | $4.22 | $106K | 627K |
| 2026-09-15 | Barber Daniel | President and CEO | Sell | 25K | $4.82 | $120K | 652K |
| 2026-09-09 | Korczynski Sherry | Chief Commercial Officer | Sell | 9K | $5.22 | $46K | 236K |
| 2026-09-09 | Korczynski Sherry | Chief Commercial Officer | Exercise or conversion | 9K | $2.65 | $23K | 244K |
| 2026-09-09 | Boyd Peter E. | Chief People Officer | Exercise (in or at the money) | 2K | $0.96 | $2K | 284K |
| 2026-09-08 | Barber Daniel | President and CEO | Exercise (in or at the money) | 92K | $0.96 | $88K | 677K |
| 2026-09-03 | Jung Cassie | Chief Operating Officer | Exercise (in or at the money) | 5K | $0.96 | $4K | 207K |
| 2026-08-17 | Barber Daniel | President and CEO | Sell | 25K | $4.29 | $107K | 586K |
| 2026-08-14 | Korczynski Sherry | Chief Commercial Officer | Tax withholding | 3K | $4.25 | $12K | 236K |
| 2026-07-16 | Barber Daniel | President and CEO | Sell | 20K | $4.00 | $82K | 611K |
| 2026-07-15 | Barber Daniel | President and CEO | Sell | 5K | $4.03 | $19K | 631K |
| 2026-06-23 | Krop Julie | Director | Sell | 25K | $5.02 | $125K | 0 |
| 2026-06-23 | Krop Julie | Director | Exercise or conversion | 25K | $0.71 | $18K | 25K |
| 2026-06-15 | Barber Daniel | President and CEO | Sell | 25K | $4.16 | $104K | 636K |
| 2026-06-08 | Korczynski Sherry | Chief Commercial Officer | Tax withholding | 3K | $0.00 | $0 | 238K |
| 2026-05-18 | Zalewski Thomas A. | Chief Legal Officer | Grant | 100K | $0.00 | $0 | 100K |
| 2026-05-15 | Barber Daniel | President and CEO | Sell | 8K | $4.29 | $35K | 661K |
| 2026-05-15 | Cioffi Melina | SVP, Regulatory Affairs | Tax withholding | 2K | $4.17 | $7K | 273K |
| 2026-05-07 | BRAENDER LORI J | Corporate Secretary | Tax withholding | 136K | $4.23 | $574K | 231K |
| 2026-05-05 | Boyd Peter E. | Chief People Officer | Tax withholding | 57K | $4.18 | $237K | 282K |
| 2026-05-05 | Barber Daniel | President and CEO | Tax withholding | 336K | $4.18 | $1.4M | 669K |
| 2026-05-05 | TOTH A ERNEST JR | Chief Financial Officer | Tax withholding | 93K | $4.18 | $387K | 283K |
| 2026-05-05 | Jung Cassie | Chief Operating Officer | Tax withholding | 73K | $4.18 | $304K | 202K |
| 2026-05-05 | BRAENDER LORI J | Corporate Secretary | Tax withholding | 76K | $4.18 | $318K | 367K |
| 2026-03-10 | Boyd Peter E. | Chief People Officer | Sell | 30K | $4.17 | $124K | 339K |
| 2026-03-10 | Barber Daniel | President and CEO | Sell | 181K | $4.17 | $754K | 1.0M |
| 2026-03-10 | BRAENDER LORI J | Chief Legal Officer | Sell | 40K | $4.17 | $167K | 443K |
| 2026-03-10 | Cioffi Melina | SVP, Regulatory Affairs | Sell | 25K | $4.17 | $106K | 275K |
| 2026-03-10 | TOTH A ERNEST JR | Chief Financial Officer | Sell | 58K | $4.17 | $243K | 376K |
| 2026-03-10 | Korczynski Sherry | Chief Commercial Officer | Sell | 16K | $4.17 | $66K | 241K |
| 2026-03-10 | Jung Cassie | Chief Operating Officer | Sell | 46K | $4.17 | $191K | 275K |
| 2026-03-09 | Boyd Peter E. | Chief People Officer | Grant | 80K | $0.00 | $0 | 368K |
| 2026-03-09 | Barber Daniel | President and CEO | Grant | 262K | $0.00 | $0 | 1.2M |
| 2026-03-09 | BRAENDER LORI J | Chief Legal Officer | Grant | 80K | $0.00 | $0 | 483K |
| 2026-03-09 | Cioffi Melina | SVP, Regulatory Affairs | Grant | 100K | $0.00 | $0 | 300K |
| 2026-03-09 | TOTH A ERNEST JR | Chief Financial Officer | Grant | 95K | $0.00 | $0 | 434K |
| 2026-03-09 | Korczynski Sherry | Chief Commercial Officer | Grant | 75K | $0.00 | $0 | 257K |
| 2026-03-09 | Jung Cassie | Chief Operating Officer | Grant | 80K | $0.00 | $0 | 321K |
| 2026-03-09 | Davis Matthew W. | Chief Development Officer | Grant | 50K | $0.00 | $0 | 100K |
| 2026-03-09 | Greenhawt Matthew J. | Chief Medical Officer | Grant | 75K | $0.00 | $0 | 75K |
| 2025-12-04 | Boyd Peter E. | Chief People Officer | Grant | 20K | $0.00 | $0 | 288K |
| 2025-12-02 | Cioffi Melina | SVP, Regulatory Affairs | Tax withholding | 2K | $5.93 | $12K | 200K |
| 2025-11-10 | Davis Matthew W. | Chief Development Officer | Grant | 50K | $0.00 | $0 | 50K |
| 2025-10-15 | Jung Cassie | Chief Operating Officer | Sell | 68K | $7.01 | $474K | 241K |
| 2025-10-15 | Jung Cassie | Chief Operating Officer | Exercise or conversion | 25K | $3.10 | $78K | 308K |
| 2025-10-15 | Kraus Carl N | Chief Medical Officer | Sell | 20K | $7.00 | $142K | 282K |
| 2025-10-15 | Boyd Peter E. | See Remarks | Sell | 10K | $7.00 | $70K | 268K |
| 2025-09-26 | Barber Daniel | President and CEO | Sell | 91K | $6.03 | $551K | 923K |
| 2025-09-26 | Boyd Peter E. | See Remarks | Sell | 10K | $6.30 | $63K | 278K |
| 2025-09-19 | Barber Daniel | President and CEO | Sell | 400 | $6.00 | $2K | 1.0M |
| 2025-09-05 | Boyd Peter E. | See Remarks | Sell | 15K | $5.30 | $80K | 288K |
| 2025-09-04 | Jung Cassie | Chief Operating Officer | Exercise or conversion | 25K | $0.71 | $18K | 346K |
| 2025-09-04 | Jung Cassie | Chief Operating Officer | Sell | 62K | $5.00 | $311K | 283K |
| 2025-09-04 | Jung Cassie | Chief Operating Officer | Exercise or conversion | 25K | $3.15 | $79K | 321K |
| 2025-08-14 | Korczynski Sherry | Chief Commercial Officer | Grant | 25K | $0.00 | $0 | 182K |
| 2025-08-09 | Kraus Carl N | Chief Medical Officer | Tax withholding | 11K | $3.90 | $42K | 303K |
| 2025-06-09 | Korczynski Sherry | SVP Sales and Marketing | Tax withholding | 3K | $3.54 | $10K | 157K |
| 2025-05-15 | Cioffi Melina | SVP, Regulatory Affairs | Grant | 20K | $0.00 | $0 | 202K |
| 2025-03-10 | Jung Cassie | Chief Operating Officer | Tax withholding | 2K | $2.54 | $6K | 296K |
| 2025-03-10 | Wargacki Stephen | Chief Science Officer | Tax withholding | 5K | $2.54 | $12K | 344K |
| 2025-03-09 | Barber Daniel | President and CEO | Tax withholding | 54K | $2.65 | $143K | 1.0M |
| 2025-03-09 | Boyd Peter E. | See Remark | Tax withholding | 8K | $2.65 | $20K | 303K |
| 2025-03-09 | BRAENDER LORI J | Chief Legal Officer | Tax withholding | 11K | $2.65 | $28K | 403K |
| 2025-03-09 | TOTH A ERNEST JR | Chief Financial Officer | Tax withholding | 9K | $2.65 | $23K | 339K |
| 2025-03-09 | Jung Cassie | Chief Operating Officer | Tax withholding | 8K | $2.65 | $21K | 298K |
| 2025-03-09 | Wargacki Stephen | Chief Science Officer | Tax withholding | 15K | $2.65 | $41K | 348K |
| 2025-03-07 | Barber Daniel | President and CEO | Grant | 272K | $0.00 | $0 | 1.1M |
| 2025-03-07 | Barber Daniel | President and CEO | Tax withholding | 29K | $2.65 | $78K | 1.1M |
| 2025-03-07 | Boyd Peter E. | See Remark | Grant | 80K | $0.00 | $0 | 318K |
| 2025-03-07 | Boyd Peter E. | See Remark | Tax withholding | 7K | $2.65 | $18K | 311K |
| 2025-03-07 | BRAENDER LORI J | Chief Legal Officer | Tax withholding | 10K | $2.65 | $25K | 414K |
| 2025-03-07 | BRAENDER LORI J | Chief Legal Officer | Grant | 110K | $0.00 | $0 | 423K |
| 2025-03-07 | Korczynski Sherry | SVP Sales and Marketing | Tax withholding | 5K | $2.65 | $14K | 160K |
| 2025-03-07 | Korczynski Sherry | SVP Sales and Marketing | Grant | 90K | $0.00 | $0 | 165K |
| 2025-03-07 | Kraus Carl N | Chief Medical Officer | Grant | 70K | $0.00 | $0 | 322K |
| 2025-03-07 | Kraus Carl N | Chief Medical Officer | Tax withholding | 8K | $2.65 | $22K | 314K |
| 2025-03-07 | TOTH A ERNEST JR | Chief Financial Officer | Tax withholding | 10K | $2.65 | $27K | 348K |
| 2025-03-07 | TOTH A ERNEST JR | Chief Financial Officer | Grant | 110K | $0.00 | $0 | 358K |
| 2025-03-07 | Jung Cassie | Chief Operating Officer | Tax withholding | 7K | $2.65 | $20K | 306K |
| 2025-03-07 | Jung Cassie | Chief Operating Officer | Grant | 80K | $0.00 | $0 | 313K |
| 2025-03-07 | Wargacki Stephen | Chief Science Officer | Tax withholding | 13K | $2.65 | $34K | 364K |
| 2025-03-07 | Wargacki Stephen | Chief Science Officer | Grant | 115K | $0.00 | $0 | 376K |
| 2024-12-02 | BRATTON DOUGLAS K | TenPercentOwner | Gift | 40K | $0.00 | $0 | 200K |
| 2024-11-26 | Jung Cassie | Chief Operating Officer | Sell | 44 | $4.87 | $214 | 0 |
| 2024-08-09 | Kraus Carl N | Chief Medical Officer | Tax withholding | 11K | $3.43 | $37K | 252K |
| 2024-06-07 | Korczynski Sherry | SVP Sales and Marketing | Grant | 25K | $0.00 | $0 | 25K |
| 2024-05-10 | Wargacki Stephen | Chief Science Officer | Grant | 10K | $0.00 | $0 | 268K |
| 2024-03-15 | Schobel Alexander Mark | Chief Innovation/Tech Officer | Sell | 50K | $6.00 | $300K | 984K |
| 2024-03-10 | Jung Cassie | SVP, Operations | Tax withholding | 1K | $4.88 | $6K | 238K |
| 2024-03-10 | Wargacki Stephen | SVP, Research & Development | Tax withholding | 2K | $4.88 | $8K | 258K |
| 2024-03-09 | Jung Cassie | SVP, Operations | Tax withholding | 14K | $4.88 | $69K | 233K |
| 2024-03-09 | Barber Daniel | President and CEO | Tax withholding | 57K | $4.88 | $277K | 826K |
| 2024-03-09 | Wargacki Stephen | Chief Science Officer | Tax withholding | 20K | $4.88 | $95K | 261K |
| 2024-03-09 | Schobel Alexander Mark | Chief Innovation/Tech Officer | Tax withholding | 10K | $4.88 | $47K | 981K |
| 2024-03-09 | Schobel Alexander Mark | Chief Innovation/Tech Officer | Tax withholding | 6K | $4.88 | $29K | 1.0M |
| 2024-03-09 | Jung Cassie | SVP, Operations | Tax withholding | 8K | $4.88 | $41K | 239K |
| 2024-03-09 | Wargacki Stephen | SVP, Research & Development | Tax withholding | 11K | $4.88 | $55K | 260K |
| 2024-03-09 | TOTH A ERNEST JR | SVP, Chief Financial Officer | Tax withholding | 12K | $4.88 | $57K | 248K |
| 2024-03-09 | BRAENDER LORI J | SVP, General Counsel | Tax withholding | 11K | $4.88 | $51K | 313K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON14 Form 144 notices on file for AQST worth $2.4M at the prices reported; 3 in the last 90 days worth $396K. Latest: Daniel Barber filed on 2026-09-15 to sell 50,000 shares ($244K) from 2026-09-15.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-15 | Daniel BarberDirector, Officer | 50K | $244K | 0.040% | 2026-09-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-09 | Sherry M. KorczynskiOfficer | 9K | $46K | 0.007% | 2026-09-09 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-17 | Daniel BarberOfficer | 25K | $106K | 0.020% | 2026-08-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-15 | Daniel BarberOfficer | 25K | $101K | 0.020% | 2026-07-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | JULIE KROPDirector | 25K | $118K | 0.020% | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-15 | Daniel BarberOfficer | 25K | $104K | 0.020% | 2026-06-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-15 | Daniel BarberOfficer | 8K | $39K | 0.007% | 2026-05-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-17 | Carl N. KrausAffiliate | 53K | $286K | 0.053% | 2025-11-17 | J.P. Morgan Securities LLC |
| 2025-10-15 | Carl N. KrausOfficer | 41K | $279K | 0.041% | 2025-10-15 | J.P. Morgan Securities LLC |
| 2025-10-15 | CASSIE JUNGOfficer | 68K | $465K | 0.068% | 2025-10-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-15 | Peter BoydOfficer | 10K | $70K | 0.010% | 2025-10-15 | Merrill |
| 2025-09-29 | Peter BoydOfficer | 10K | $63K | 0.010% | 2025-09-26 | Merrill |
| 2025-09-26 | DANIEL BARBERDirector, Officer | 91K | $480K | 0.092% | 2025-09-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-19 | DANIEL R BARBEROfficer | 400 | $2K | 0.000% | 2025-09-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON5 holders report 5% or more of AQST in their latest filing, all on Schedule 13G (passive). The largest reported stake is Bass Edward P at 7.5% of the class (9,385,561 shares), filed 2026-10-07 for an event on 2026-10-07.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-07 | 13G | Bass Edward Pindividual | 9.4M | 7.5% | 2026-10-07 |
| 2026-10-07 | 13G | THRU LINE L.P.partnership | 7.9M | 6.3% | 2026-10-07 |
| 2026-10-07 | 13G/Ano. 5 | BRATTON DOUGLAS Kindividual | 692K | 0.6% | 2026-10-07 |
| 2026-10-07 | 13G/Ano. 5 | Bratton Capital Inc.corporation | 392K | 0.3% | 2026-10-07 |
| 2026-10-07 | 13G/Ano. 5 | Bratton Capital Management, L.P.partnership | 391K | 0.3% | 2026-10-07 |
| 2026-10-07 | 13G/Ano. 5 | MonoLine RX II, L.P.partnership | 0 | 0.0% | 2026-10-07 |
| 2026-10-07 | 13G/Ano. 5 | MonoLine RX, L.P.partnership | 0 | 0.0% | 2026-10-07 |
| 2026-10-07 | 13G/Ano. 5 | Bratton Family Partners L.P.partnership | 34K | 0.0% | 2026-10-07 |
| 2026-10-07 | 13G/Ano. 5 | MonoSol Rx Genpar, L.P.partnership | 0 | 0.0% | 2026-10-07 |
| 2026-10-07 | 13G/Ano. 5 | MonoLine Partners, L.P.partnership | 0 | 0.0% | 2026-10-07 |
| 2026-10-07 | 13G/Ano. 5 | MonoLine RX III, L.P.partnership | 0 | 0.0% | 2026-10-07 |
| 2026-07-27 | 13G/Ano. 2 | BlackRock, Inc.parent holding company | 8.0M | 6.4% | 2026-06-30 |
| 2025-11-14 | 13G | RTW Investments, LPinvestment adviser, partnership | 6.3M | 5.2% | 2025-09-30 |
| 2025-11-14 | 13G | Roderick Wongparent holding company, individual | 6.3M | 5.2% | 2025-09-30 |
13F holders
Tracked managers holding AQST at their latest 13F. JSON5 of the 30 tracked managers held AQST at their latest 13F, $9.9M in total at quarter-end prices. Two Sigma Investments is the largest at $5.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.3M | $5.3M | 0.00% | +142K |
| Citadel Advisors | 2026-06-30 | 452K | $1.9M | 0.00% | -113K |
| Renaissance Technologies | 2026-06-30 | 416K | $1.7M | 0.00% | new |
| AQR Capital Management | 2026-06-30 | 202K | $840K | 0.00% | +150K |
| D. E. Shaw & Co. | 2026-06-30 | 38K | $157K | 0.00% | +19K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Aquestive Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Aquestive Therapeutics (AQST), SEC CIK 1398733, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-23.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-25.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-15.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-21.JSON and CSV
- Company record
- EDGAR filing index for CIK 1398733Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of AQST is sold short?
28,748,212 shares were held short at the 2026-09-30 settlement, 13.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is AQST's daily short volume?
On 2026-10-23, 643,462 of the 981,002 AQST shares reported to FINRA were sold short, 65.6% of the day's reported volume. Short volume is a flow for one day, not a position.
Does AQST have fails to deliver?
The SEC's latest file shows 2,179 AQST shares failed to deliver at settlement 2026-09-25. Fails are reported per settlement date and published twice a month with a lag.
Are AQST insiders buying or selling?
Insiders at AQST reported 4 open-market sells worth $379K in the last 90 days and no open-market buys. Latest filing: Cochran John (Director) on 2026-10-21.
Have AQST insiders filed to sell?
14 Form 144 notices on file for AQST worth $2.4M at the prices reported; 3 in the last 90 days worth $396K. Latest: Daniel Barber filed on 2026-09-15 to sell 50,000 shares ($244K) from 2026-09-15.
Who owns 5% or more of AQST?
5 holders report 5% or more of AQST in their latest filing, all on Schedule 13G (passive). The largest reported stake is Bass Edward P at 7.5% of the class (9,385,561 shares), filed 2026-10-07 for an event on 2026-10-07.
Which tracked 13F managers own AQST?
5 of the 30 tracked 13F managers held AQST shares at their latest filing, $9.9M in all. The largest: Two Sigma Investments (1.3M shares, $5.3M), Ken Griffin's Citadel Advisors (452K shares, $1.9M), Renaissance Technologies (416K shares, $1.7M), Cliff Asness's AQR Capital Management (202K shares, $840K), D. E. Shaw & Co. (38K shares, $157K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.